Brief: Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold On Nx-2127 Phase 1 Trial
11/03/2024 11:47
March 11 (Reuters) - Nurix Therapeutics Inc NRIX.O :
* NURIX THERAPEUTICS ANNOUNCES U.S. FDA LIFTS PARTIAL
CLINICAL
HOLD ON NX-2127 PHASE 1 TRIAL
* NURIX: TO REINITIATE ENROLLMENT WITH NEW CHIRALLY
CONTROLLED
DRUG SUBSTANCE IN STANDARD DOSE ESCALATION STUDY WITHIN CURRENT
PHASE 1A/1B TRIAL
Source text for Eikon: ID:nGNX532kFV
Further company coverage: NRIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nurix Therapeutics
See all newsNurix Therapeutics Q3 swings to profit on Roche collaboration
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis